Moss, 25 August 2022

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the second quarter and first half of
2022.

Highlights
* Record sales of MNOK 30.1 in 2Q22, up 22% and 19% organically from 2Q21
despite COVID-19 related logistics challenges in China

* An additional distribution agreement with a global diagnostics company for
Cystatin C announced post quarter with initial rollout in North America

* Established a Scientific Advisory Board for GCAL® with Key Opinion Leaders
from Europe and participation from Siemens Healthineers to further accelerate
market development

* Good progress made on NT-proBNP, promising new immonuparticle candidate
identified

* Successfully completed extension of the lab and production facilities in Moss
designed to support long-term revenue ambition

* Current demand and commercial progress support ambition of 20% annual sales
growth from established products, with further upside from products in market
development

"For the second half of 2022, we aim to expand our footprint through additional
regulatory approvals including IVDR, and further clinical studies and
endorsements from key opinion leaders. We are also working on maturing our three
projects currently in exploration and proof of concept phases with the aim to
broaden our product portfolio and addressable market," commented Hilja Ibert,
CEO of Gentian Diagnostics.

For NT-proBNP, earlier issues related to interference and signal strength appear
less pronounced following the identification of a promising new immunoparticle
candidate during the second quarter. More investigations are still required to
further improve signal strength and clinical samples must be tested to reproduce
early findings. 


Webcast
Gentian's CEO Hilja Ibert and CFO Njaal Kind will present the results today at
10.00 am, followed by a Q&A session. Join the webcast and submit questions via
the following link:

https://attendee.gotowebinar.com/register/7206975888818806799

The webcast will be made available on the company's IR website after the
presentation.


IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 25 August 2022 at 08:00 CET.


About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.